Patent ID: 8257744
Filing Date: 2012-09-04
Classification: A61K,A61P

Abstract:
1. A pharmaceutical form, which is a granule or pellet, having an average particle diameter in the range of 0.1 to 1.2 mm and comprising at least one active compound and a polymeric matrix, wherein: a) the active compound is selected from the group consisting of: antibiotics, anti-inflammatory agents, anti-infectious agents, antiparasitic agents, hormones, substances with immunological activity, vaccines, immunomodulators, immunosuppressants, cytostatic agents, diuretics, agents with activity in the digestive system, agents with activity in the circulatory system, agents with activity in the respiratory system, human growth hormone, recombinant growth hormone, bovine growth hormone, growth-hormone releasing hormone, interferons, analgesics, agents with activity in the central nervous system, erythropoietin, somatostatin, gonadotropin-releasing hormone, follicle-stimulating hormone, oxytocin, vasopressin, parathyroid hormone, adrenocorticotropin, gonadotropin-releasing hormone, thrombopoietin, calcitonin, interferons, interleukins, insulins, unfractionated heparin, low molecular weight heparin, ultra-low molecular weight heparins, heparinoids, dermatan, glucosamines, chondroitins, auricular natriuretic factor, monoclonal antibodies, protease inhibitors, filgrastim, prostaglandins (PGE2 and PGI2), cyclosporin, cromolyn sodium, cromoglycate and its salts, vasopressin, vancomycin, neomycin, desferrioxamine, antimicrobial agents, antifungals, cytostatics, immunomodulators, vitamins, antivirals, antigens, ribonucleic acid, deoxyribonucleic acid, oligonucleotides, CPG sequences, plasmids, active compounds of protein nature, active compounds of polysaccharide nature, glucocerebrosidase, and derivatives and combinations thereof; b) the polymeric matrix comprises: c) less than 20% wt, of the active compound is distributed on the surface of the pharmaceutical form; d) at least 80% wt, of the active compound is embedded within or surrounded by the polymeric matrix of the pharmaceutical form; e) the pharmaceutical form provides a release of at least 50% of active compound that is available for immediate release within 2 hours or less after the pharmaceutical form is exposed to an aqueous environment; f) the biodegradable polymer and the polycationic polymer are present in equivalent amounts; and g) the biodegradable polymer and the polycationic polymer are non-enteric.